Towards Circulating Tumor DNA-guided Treatment of Muscle-invasive Bladder Cancer

Overview

Journal Transl Androl Urol

Date 2024 Jul 10

PMID 38983478

Authors

Sia Viborg Lindskrog

Lars Dyrskjot

Affiliations

Soon will be listed here.

References

Reinert T, Vesterman Henriksen T, Christensen E, Sharma S, Salari R, Sethi H . Analysis of Plasma Cell-Free DNA by Ultradeep Sequencing in Patients With Stages I to III Colorectal Cancer. JAMA Oncol. 2019; 5(8):1124-1131. PMC: 6512280. DOI: 10.1001/jamaoncol.2019.0528. View

Christensen E, Nordentoft I, Birkenkamp-Demtroder K, Elbaek S, Lindskrog S, Taber A . Cell-Free Urine and Plasma DNA Mutational Analysis Predicts Neoadjuvant Chemotherapy Response and Outcome in Patients with Muscle-Invasive Bladder Cancer. Clin Cancer Res. 2023; 29(8):1582-1591. PMC: 10102843. DOI: 10.1158/1078-0432.CCR-22-3250. View

Powles T, Assaf Z, Davarpanah N, Banchereau R, Szabados B, Yuen K . ctDNA guiding adjuvant immunotherapy in urothelial carcinoma. Nature. 2021; 595(7867):432-437. DOI: 10.1038/s41586-021-03642-9. View

Zargar H, Espiritu P, Fairey A, Mertens L, Dinney C, Mir M . Multicenter assessment of neoadjuvant chemotherapy for muscle-invasive bladder cancer. Eur Urol. 2014; 67(2):241-9. PMC: 4840190. DOI: 10.1016/j.eururo.2014.09.007. View

Abbosh C, Birkbak N, Wilson G, Jamal-Hanjani M, Constantin T, Salari R . Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature. 2017; 545(7655):446-451. PMC: 5812436. DOI: 10.1038/nature22364. View

Powles T, Assaf Z, Degaonkar V, Grivas P, Hussain M, Oudard S . Updated Overall Survival by Circulating Tumor DNA Status from the Phase 3 IMvigor010 Trial: Adjuvant Atezolizumab Versus Observation in Muscle-invasive Urothelial Carcinoma. Eur Urol. 2023; 85(2):114-122. DOI: 10.1016/j.eururo.2023.06.007. View

Lindskrog S, Birkenkamp-Demtroder K, Nordentoft I, Laliotis G, Lamy P, Christensen E . Circulating Tumor DNA Analysis in Advanced Urothelial Carcinoma: Insights from Biological Analysis and Extended Clinical Follow-up. Clin Cancer Res. 2023; 29(23):4797-4807. PMC: 10690087. DOI: 10.1158/1078-0432.CCR-23-1860. View

Khier S, Lohan L . Kinetics of circulating cell-free DNA for biomedical applications: critical appraisal of the literature. Future Sci OA. 2018; 4(4):FSO295. PMC: 5905581. DOI: 10.4155/fsoa-2017-0140. View

Tie J, Cohen J, Lahouel K, Lo S, Wang Y, Kosmider S . Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer. N Engl J Med. 2022; 386(24):2261-2272. PMC: 9701133. DOI: 10.1056/NEJMoa2200075. View

10.

Christensen E, Birkenkamp-Demtroder K, Sethi H, Shchegrova S, Salari R, Nordentoft I . Early Detection of Metastatic Relapse and Monitoring of Therapeutic Efficacy by Ultra-Deep Sequencing of Plasma Cell-Free DNA in Patients With Urothelial Bladder Carcinoma. J Clin Oncol. 2019; 37(18):1547-1557. DOI: 10.1200/JCO.18.02052. View

11.

Kotani D, Oki E, Nakamura Y, Yukami H, Mishima S, Bando H . Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer. Nat Med. 2023; 29(1):127-134. PMC: 9873552. DOI: 10.1038/s41591-022-02115-4. View

12.

Jakobsen A, Spindler K . ctDNA-Response evaluation criteria in solid tumors - a new measure in medical oncology. Eur J Cancer. 2023; 180:180-183. DOI: 10.1016/j.ejca.2022.11.039. View

13.

Jackson-Spence F, Toms C, OMahony L, Choy J, Flanders L, Szabados B . IMvigor011: a study of adjuvant atezolizumab in patients with high-risk MIBC who are ctDNA+ post-surgery. Future Oncol. 2023; 19(7):509-515. DOI: 10.2217/fon-2022-0868. View

14.

Bellmunt J, Hussain M, Gschwend J, Albers P, Oudard S, Castellano D . Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2021; 22(4):525-537. PMC: 8495594. DOI: 10.1016/S1470-2045(21)00004-8. View

15.

Nordentoft I, Lindskrog S, Birkenkamp-Demtroder K, Gonzalez S, Kuzman M, Levatic J . Whole-genome Mutational Analysis for Tumor-informed Detection of Circulating Tumor DNA in Patients with Urothelial Carcinoma. Eur Urol. 2024; 86(4):301-311. DOI: 10.1016/j.eururo.2024.05.014. View

16.

Niedersuss-Beke D, Puntus T, Kunit T, Grunberger B, Lamche M, Loidl W . Neoadjuvant Chemotherapy with Gemcitabine plus Cisplatin in Patients with Locally Advanced Bladder Cancer. Oncology. 2017; 93(1):36-42. DOI: 10.1159/000463389. View

17.

Li R . Organ-sparing precision treatment for muscle-invasive bladder cancer. Nat Med. 2023; 29(11):2709-2710. DOI: 10.1038/s41591-023-02575-2. View

18.

Szabados B, Kockx M, Assaf Z, Van Dam P, Rodriguez-Vida A, Duran I . Final Results of Neoadjuvant Atezolizumab in Cisplatin-ineligible Patients with Muscle-invasive Urothelial Cancer of the Bladder. Eur Urol. 2022; 82(2):212-222. DOI: 10.1016/j.eururo.2022.04.013. View